Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Nanomedicine (Lond). 2015 Jul;10(12):1881–1897. doi: 10.2217/nnm.15.37

Figure 4. Complete inhibition of viral assembly in vivo by mutant pRNA as a model of drugged complex (Z = 6).

Figure 4

(A) Inactivation of pRNA by introducing a 4-nucleotide mutation at the 3´end. (B) Virion production by wild-type phi29 infection using host cell B. subtilis harboring plasmid expressing mutant pRNA, wild-type pRNA or plasmid only.